Literature DB >> 11073020

Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study.

J J Hospers1, D S Postma, B Rijcken, S T Weiss, J P Schouten.   

Abstract

BACKGROUND: Smoking and airway lability, which is expressed by histamine airway hyper-responsiveness, are known risk factors for development of respiratory symptoms. Smoking is also associated with increased mortality risks. We studied whether airway hyper-responsiveness is associated with increased mortality, and whether this risk was independent of smoking and reduced lung function.
METHODS: We followed up 2008 inhabitants of the communities of Vlagtwedde, Vlaardingen, and Meppel (Netherlands), who had histamine challenge test data, from 1964-72 for 30 years. Follow-up was 99% successful (29 patients lost to follow-up) with 1453 participants alive and 526 deaths (246 died from cardiovascular disease, 54 from lung cancer, and 21 from chronic obstructive pulmonary disease [COPD]).
FINDINGS: Mortality from COPD increased with more severe hyper-responsiveness; relative risks of 3.83 (95% CI 0.97-15.1), 4.40 (1.16-16.7), 4.78 (1.27-18.0), 6.69 (1.71-26.1), and 15.8 (3.72-67.1) were associated with histamine thresholds of 32 g/L, 16 g/L, 8 g/L, 4 g/L, and 1 g/L, respectively, compared with no hyper-responsiveness. These risks were adjusted for sex, age, smoking, lung function, body-mass index, positive skin tests, eosinophilia, asthma, and city of residence.
INTERPRETATION: Increased histamine airway hyper-responsiveness predicts mortality from COPD. Although this trend was more pronounced in smokers, an increasing proportion of COPD deaths with increasing hyper-responsiveness was also present among individuals who had never smoked.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11073020     DOI: 10.1016/S0140-6736(00)02815-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  48 in total

Review 1.  Airway hyperresponsiveness and COPD mortality.

Authors:  J Vestbo; E F Hansen
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Beta2-adrenergic receptor polymorphisms are associated with asthma and COPD in adults.

Authors:  Melanie C Matheson; Justine A Ellis; Joan Raven; David P Johns; E Haydn Walters; Michael J Abramson
Journal:  J Hum Genet       Date:  2006-09-01       Impact factor: 3.172

3.  Respiratory effects of environmental tobacco exposure are enhanced by bronchial hyperreactivity.

Authors:  Margaret W Gerbase; Christian Schindler; Jean-Pierre Zellweger; Nino Künzli; Sara H Downs; Otto Brändli; Joel Schwartz; Martin Frey; Luc Burdet; Thierry Rochat; Ursula Ackermann-Liebrich; Philippe Leuenberger
Journal:  Am J Respir Crit Care Med       Date:  2006-08-24       Impact factor: 21.405

4.  Prediction of chronic obstructive pulmonary disease (COPD) in asthma patients using electronic medical records.

Authors:  Blanca E Himes; Yi Dai; Isaac S Kohane; Scott T Weiss; Marco F Ramoni
Journal:  J Am Med Inform Assoc       Date:  2009-03-04       Impact factor: 4.497

5.  Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma.

Authors:  M J McGeachie; K P Yates; S T Weiss; R C Strunk; X Zhou; F Guo; A L Sternberg; M L Van Natta; R A Wise; S J Szefler; S Sharma; A T Kho; M H Cho; D C Croteau-Chonka; P J Castaldi; G Jain; A Sanyal; Y Zhan; B R Lajoie; J Dekker; J Stamatoyannopoulos; R A Covar; R S Zeiger; N F Adkinson; P V Williams; H W Kelly; H Grasemann; J M Vonk; G H Koppelman; D S Postma; B A Raby; I Houston; Q Lu; A L Fuhlbrigge; K G Tantisira; E K Silverman; J Tonascia
Journal:  N Engl J Med       Date:  2016-05-12       Impact factor: 91.245

Review 6.  Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?

Authors:  S F Paul Man; Don D Sin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Water content of delivered gases during non-invasive ventilation in healthy subjects.

Authors:  François Lellouche; Salvatore Maurizio Maggiore; Aissam Lyazidi; Nicolas Deye; Solenne Taillé; Laurent Brochard
Journal:  Intensive Care Med       Date:  2009-03-18       Impact factor: 17.440

Review 8.  Clinical implications of airway hyperresponsiveness in COPD.

Authors:  Nicola Scichilone; Salvatore Battaglia; Alba La Sala; Vincenzo Bellia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 9.  Smoking cessation therapy with varenicline.

Authors:  Uma M Mohanasundaram; Rajinder Chitkara; Ganesh Krishna
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

10.  ICS and COPD: time to clear the air.

Authors:  Paul A Ford; Richard E K Russell; Peter J Barnes
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.